The FDA doesn't publish a pen testing checklist, but its guidance, 524B requirements, and reviewer expectations add up to one. Here's what medical device makers must cover before, during, and after the test.

Standard pen test scoping frameworks weren't built for pharma. Learn how to scope an engagement that covers validated systems under 21 CFR Part 11 and protects high-value formulation and clinical data from targeted threats.

Section 524B made medical device cybersecurity a legal requirement, not a guideline. Learn what the FDA expects from your pen test scope, evidence package, and postmarket vulnerability management process.

Completing a pen test isn't enough for CMMC. Learn what C3PAO assessors actually look for in your evidence package and how to align your report, scope, POA&M, and remediation docs to specific practice statements.

21 CFR Part 11 and cGMP don't mention penetration testing but the controls they require depend on it. Learn how to align your pharma pen test program with regulatory requirements and prepare for FDA data integrity inspections.